Restylane Lyft Approved for Cheek Augmentation and Midface Contour Deficiencies

The FDA approved Galderma's Restylane Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. Restylane Lyft, formerly marketed as Perlane-L, is an injectable gel used to increase volume and smooth wrinkles in the face. With this new indication, Restylane Lyft is the only FDA approved filler indicated to provide fullness to the midface area and to correct and smooth the nasolabial folds. 

In a clinical trial involving 200 patients, investigators observed that 88.7 percent of patients treated with Restylane Lyft showed an improvement in fullness in the right and left midface areas (combined) at two months, and more than half maintained improvement for 12 months. Additionally, 95 percent of patients reported improvement with the appearance of their midface at two months and 73 percent of patients reported improvement at 12 months. The most common adverse events observed in the trial included: tenderness, redness, bruising, swelling and itching. These events decreased in severity over time and most were resolved within two weeks.